Oren Fruchter1, Mordechai Yigla, Mordechai R Kramer. 1. Pulmonary Division (OF, MRK), Rabin Medical Center, Petah Tiqwa, Israel; The Sackler School of Medicine (OF, MRK), Tel Aviv University, Tel Aviv, Israel; and Pulmonary Division (MY), Rambam Medical Center, Haifa, Israel.
Abstract
BACKGROUND: A major barrier to chronic obstructive pulmonary disease (COPD) research and management is lack of easily obtained biomarkers that are predictive of clinically important outcome measures. OBJECTIVES: We sought to investigate in patients admitted for acute exacerbation of COPD (AECOPD) the association of D-dimer (fibrin degradation product) obtained upon admission with in-hospital mortality and postdischarge prognosis. METHODS: Clinical and laboratory data were evaluated in 61 patients admitted for AECOPD in whom D-dimer levels were obtained and in whom venous thromboembolism/pulmonary embolism was excluded. Receiver operating characteristics curve was used to determine the optimal cutoff level for D-dimer that discriminated survivors versus nonsurvivors during index hospitalization, and during follow-up that extended to a median observation period of 62.6 months. RESULTS: Mean (± SD) age of the study cohort was 71.2 ± 10.5 years. Mean D-dimer level in nonsurvivors (n = 12) was significantly higher than in survivors (n = 49): 3.18 ± 0.97 mg/L versus 1.45 ± 1.18 mg/L, respectively, P = 0.0006. D-dimer level >1.52 mg/L predicted in-hospital mortality with a sensitivity and specificity of 100% and 63.6%, respectively. After discharge, median survival of patients with D-dimer above and below 1.52 mg/L were 9.6 and 62.6 months, respectively (hazard ratio = 2.636; 95% confidence interval = 1.271-6.426, P = 0.0111). CONCLUSIONS: Elevated D-dimer is a reliable prognostic marker for both short-term and long-term survival in patients admitted for AECOPD. Prospective studies are required to further establish the appropriate role of D-dimer as a prognostic biomarker in patients with COPD.
BACKGROUND: A major barrier to chronic obstructive pulmonary disease (COPD) research and management is lack of easily obtained biomarkers that are predictive of clinically important outcome measures. OBJECTIVES: We sought to investigate in patients admitted for acute exacerbation of COPD (AECOPD) the association of D-dimer (fibrin degradation product) obtained upon admission with in-hospital mortality and postdischarge prognosis. METHODS: Clinical and laboratory data were evaluated in 61 patients admitted for AECOPD in whom D-dimer levels were obtained and in whom venous thromboembolism/pulmonary embolism was excluded. Receiver operating characteristics curve was used to determine the optimal cutoff level for D-dimer that discriminated survivors versus nonsurvivors during index hospitalization, and during follow-up that extended to a median observation period of 62.6 months. RESULTS: Mean (± SD) age of the study cohort was 71.2 ± 10.5 years. Mean D-dimer level in nonsurvivors (n = 12) was significantly higher than in survivors (n = 49): 3.18 ± 0.97 mg/L versus 1.45 ± 1.18 mg/L, respectively, P = 0.0006. D-dimer level >1.52 mg/L predicted in-hospital mortality with a sensitivity and specificity of 100% and 63.6%, respectively. After discharge, median survival of patients with D-dimer above and below 1.52 mg/L were 9.6 and 62.6 months, respectively (hazard ratio = 2.636; 95% confidence interval = 1.271-6.426, P = 0.0111). CONCLUSIONS: Elevated D-dimer is a reliable prognostic marker for both short-term and long-term survival in patients admitted for AECOPD. Prospective studies are required to further establish the appropriate role of D-dimer as a prognostic biomarker in patients with COPD.
Authors: Ning Xu; Juan Chen; Xin Chang; Jingwen Zhang; Qinghua Liu; Aljun Li; Dianjie Lin Journal: Ann Saudi Med Date: 2016 Jan-Feb Impact factor: 1.526
Authors: Qiuying Chen; Ruba S Deeb; Yuliang Ma; Michelle R Staudt; Ronald G Crystal; Steven S Gross Journal: PLoS One Date: 2015-12-16 Impact factor: 3.240
Authors: Fanny W Ko; Ka Pang Chan; David S Hui; John R Goddard; Janet G Shaw; David W Reid; Ian A Yang Journal: Respirology Date: 2016-03-30 Impact factor: 6.424